In 2023 the international hepatology societies updated the nomenclature: the former “non-alcoholic fatty liver disease” (NAFLD) became MASLD (metabolic dysfunction-associated steatotic liver disease), and steatohepatitis (NASH) became MASH. The change puts the focus on the metabolic cause (obesity, insulin resistance, diabetes) rather than on the absence of alcohol.
MASLD is very common in people with excess weight. In some cases the fat comes with inflammation and liver cell damage (MASH), and over the years fibrosis and, in advanced cases, cirrhosis can develop.
It is one of the most active research areas for metabolic agonists, especially those that include the glucagon receptor, because of its direct action on liver fat metabolism: survodutide, retatrutide or mazdutide.
When reading about GLP-1/glucagon agonists, fatty liver comes up constantly. Knowing the new nomenclature avoids confusion between older (NASH) and more recent (MASH) studies.
Related terms
Learn it in depth at the Peptide University
- Complementary monographs (16–20) · Module 14
Related catalogue compounds
Definition for educational and scientific purposes. It is not medical advice or a recommendation for use. NeoPeptidos products are sold labelled for research use only (RUO).